Actively Recruiting
Tissue-engineered Skin Graft Repair of Autologous Scar Dermal Scaffolds
Led by First Affiliated Hospital, Sun Yat-Sen University · Updated on 2020-05-15
226
Participants Needed
1
Research Sites
461 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hypertrophic scar is an inevitable outcome of wound repair. It affects the appearance and some scar contracture often leads to joint dysfunction.Patients have low quality of life, long treatment cycle, heavy social burden and high medical costs.Skin grafting is currently the gold standard for scar repair.However, there are often insufficient skin sources, easy to scar recurrence, lack of skin accessory organs.The application of composite skin graft can reduce the recurrence rate of scar healing and relieve the deficiency of skin source.However, its survival rate is not high, and acellular allogeneic dermal scaffolds are expensive, heavy medical burden.Therefore, how to effectively repair the wound surface after surgical excision of scar is the main problem to be solved urgently. Dermal loss is the main cause of unsatisfactory scar repair and recurrence.The previous clinical study of the research group found that the application of autologous epidermal basal cells and autologous skin graft obtained in real time during the operation could effectively improve the survival rate of skin graft in the treatment of wound surface (Brit J Surg, 2015).Furthermore, it is suggested that the application of autologous scar dermal scaffolds can achieve the control of skin damage in the skin harvesting area and the orthotopic transplantation of autologous scar tissue dermal scaffolds, which can effectively reduce the economic burden of patients.Therefore, the researchers wondered whether the construction of tissue-engineered skin orthotopic transplantation with autologous epidermal basal cells and autologous scar dermal scaffold combined with autologous scar dermal scaffolds to repair the wound after scar resection could improve the survival rate of skin graft and reduce scar recurrence.To this end, we plan to carry out multi-center, prospective, randomized, controlled clinical trials, aiming at proposing more effective surgical treatment guidelines for the repair of hypertrophic scar, improving the survival rate of composite skin graft, and solving the current clinical problems of hypertrophic scar repair.
CONDITIONS
Official Title
Tissue-engineered Skin Graft Repair of Autologous Scar Dermal Scaffolds
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with hypertrophic scar needing surgical repair
- Scar size between 10cm squared and 200cm squared at any site
- Stable vital signs and can tolerate surgery based on routine examination
- Mentally well and able to follow doctor's advice and attend regular follow-ups
You will not qualify if you...
- Does not meet the inclusion criteria
- Follow-up visits fewer than two times after inclusion, preventing evaluation of effectiveness
- Violates study protocol requirements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China, 510080
Actively Recruiting
Research Team
Z
ZHU JIAYUAN
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here